Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Current Liabilities (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Total Current Liabilities for 15 consecutive years, with $58.8 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 12.37% year-over-year to $58.8 million; the TTM value through Mar 2026 reached $58.8 million, up 12.37%, while the annual FY2025 figure was $82.2 million, 1.29% up from the prior year.
  • Total Current Liabilities hit $58.8 million in Q1 2026 for Agios Pharmaceuticals, down from $82.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $119.5 million in Q3 2024 and bottomed at $45.1 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $64.2 million, with a median of $58.8 million recorded in 2026.
  • Year-over-year, Total Current Liabilities crashed 52.55% in 2022 and then soared 104.45% in 2024.
  • Agios Pharmaceuticals' Total Current Liabilities stood at $62.6 million in 2022, then grew by 8.5% to $68.0 million in 2023, then grew by 19.43% to $81.2 million in 2024, then grew by 1.29% to $82.2 million in 2025, then decreased by 28.42% to $58.8 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $58.8 million, $82.2 million, and $74.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.